UNSPSC 51172481: Laronidase

Laronidase is a form of recombinant human alpha-L-iduronidase used to treat Hurler and Hurler-Scheie forms of mucopolysaccharidosis, a genetic deficiency of alpha-L-iduronidase

UNSPSC 51172481 Laronidase, a Commodity code, shows little relevant recent state and local procurement activity. The code encompasses pharmaceutical products used in enzyme replacement therapy, but the recent opportunities tagged under it do not align with laronidase procurement. Instead, the opportunities reflect miscellaneous county administrative notices, vendor networking events, and tangential pharmaceutical-related solicitations (naloxone distribution, emergency medical supply contracts, generic pharmaceuticals through cooperative purchasing, and drug standards for forensic analysis). None of the recent postings solicit laronidase specifically or describe treatment protocols for mucopolysaccharidosis storage disorders, which would define the core market for this commodity code.

The available opportunities do not support characterization of issuing-body concentration, geographic spread, or representative laronidase procurement. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems; Tucson, Arizona issued an RFP for emergency medical supplies and pharmacy vending systems; and Minnesota's MMCAP cooperative issued an RFP for generic multi-source pharmaceuticals and OTC products available through authorized wholesalers. These procurements address urgent care, opioid response, and general-purpose pharmacy supply chains—not specialty rare-disease enzyme therapies. Until state and local healthcare systems or specialty pharmacy vendors post laronidase-specific demand signals, activity under this code remains too sparse to support a pursue recommendation.